Interestingly, it has been observed in multiple studies that targeting NFκB signalling pathways when treating MM, reduces drug resistance to PIs30, suggesting that the significantly increased abundance of Integrin β3 shown in this study may be leading to increased levels of NFκB signalling, causing CAM-DR to three of the five drugs. This evidence concerns the gene NFKB1 and Miyoshi myopathy.